Drugs Brain and Behavior (DDP)

Stimulant Use Clinical Trial

— DDP  

Official title:

Drugs Brain and Behavior

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04642820
• Other study ID #: IRB20-0364
• Status: Recruiting
• Phase: Early Phase 1
• Start date: November 1, 2020
• Est. completion date: June 1, 2024

Study information

• Verified date: December 2023
• Source: University of Chicago
• Contact: Matthew Bona
• Phone: 773-702-3560
• Email: dewitlab[@]yoda.bsd.uchicago.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: June 1, 2024
• Est. primary completion date: October 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• BMI between 19 and 26
• Right Handed
• Less than 4 alcohol or caffeinated beverages a day.

Exclusion Criteria:

• High blood pressure
• Any medical condition requiring regular medication
• Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis
• Individuals with a history of dependence on stimulant drugs
• Women who are pregnant or trying to become pregnant.

Related Conditions & MeSH terms

• Stimulant Use

Intervention

Drug:
• Methamphetamine
Participants will be given 20 mg of Methamphetamine.
• placebo oral tablet
Participants will be given a placebo capsule that will only contain lactose.

Locations

Country	Name	City	State
United States	University of Chicago	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ).	Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: "Feel Drug", "Feel High", "Like Drug", and "Want More". All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome.	Time Frame: Day 1(baseline), 3